Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 101 to 125 of 313

Guidance and quality standards awaiting development
Title	Type
Eneboparatide for treating chronic hypoparathyroidism [TSID12145]	Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]	Technology appraisal guidance
Enlicitide decanoate for treating hyperlipidaemia in people at risk of an atherosclerotic cardiovascular disease event [ID6656]	Technology appraisal guidance
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [TSID12015]	Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]	Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]	Technology appraisal guidance
Extra-vascular implantable cardioverter defibrillator (EVICD) for people with a defibrillator	Interventional procedures guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]	Technology appraisal guidance
Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]	Technology appraisal guidance
Fenebrutinib for treating relapsing multiple sclerosis [ID6577]	Technology appraisal guidance
Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [TSID12216]	Technology appraisal guidance
Filgotinib for Axial spondyloarthritis [ID6594]	Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]	Technology appraisal guidance
Galcanezumab for migraine [TSID10663]	Technology appraisal guidance
Gambling	Quality standard
Gantenerumab for treating early Alzheimer's disease [TSID10668]	Technology appraisal guidance
Gemcitabine intravesical delivery system for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658]	Technology appraisal guidance
Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657]	Technology appraisal guidance
Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]	Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]	Technology appraisal guidance
Gout	Quality standard
Heart valve disease in adults	Quality standard
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]	Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]	Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]	Technology appraisal guidance

Results per page

10
25
50
All